NASDAQ:IRIX IRIDEX (IRIX) Stock Price, News & Analysis → Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (From Banyan Hill Publishing) (Ad) Free IRIX Stock Alerts $2.80 -0.05 (-1.75%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$2.80▼$2.9250-Day Range$2.35▼$3.5352-Week Range$1.31▼$3.65Volume16,348 shsAverage Volume33,005 shsMarket Capitalization$45.51 millionP/E RatioN/ADividend YieldN/APrice Target$2.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get IRIDEX alerts: Email Address IRIDEX MarketRank™ Stock AnalysisAnalyst Rating0.00 Rating ScoreUpside/Downside28.6% Downside$2.00 Price TargetShort InterestBearish2.74% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.37) to ($0.29) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.00 out of 5 starsComputer And Technology Sector3559th out of 3,564 stocksElectromedical Equipment Industry115th out of 120 stocks 0.0 Analyst's Opinion Amount of Analyst CoverageIRIDEX has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.74% of the float of IRIDEX has been sold short.Short Interest Ratio / Days to CoverIRIDEX has a short interest ratio ("days to cover") of 9.6.Change versus previous monthShort interest in IRIDEX has recently increased by 3.54%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldIRIDEX does not currently pay a dividend.Dividend GrowthIRIDEX does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IRIX. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for IRIDEX this week, compared to 0 articles on an average week.MarketBeat Follows1 people have added IRIDEX to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IRIDEX insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.20% of the stock of IRIDEX is held by insiders.Percentage Held by InstitutionsOnly 20.10% of the stock of IRIDEX is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for IRIDEX are expected to grow in the coming year, from ($0.37) to ($0.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IRIDEX is -4.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IRIDEX is -4.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIRIDEX has a P/B Ratio of 4.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchGold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).See his free reveal right here. About IRIDEX Stock (NASDAQ:IRIX)IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.Read More IRIX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IRIX Stock News HeadlinesMay 4, 2024 | americanbankingnews.comIRIDEX (NASDAQ:IRIX) Earns Hold Rating from Analysts at StockNews.comApril 26, 2024 | americanbankingnews.comIRIDEX (NASDAQ:IRIX) Stock Price Crosses Above 200-Day Moving Average of $2.72May 4, 2024 | Priority Gold (Ad)Biden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...April 26, 2024 | americanbankingnews.comIRIDEX (NASDAQ:IRIX) Coverage Initiated by Analysts at StockNews.comMarch 28, 2024 | benzinga.comIridex: Q4 Earnings InsightsMarch 28, 2024 | seekingalpha.comIridex's Strategic Review Process Should Bear Fruit 'Soon'March 27, 2024 | finanznachrichten.deIRIDEX Corporation: Iridex Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 27, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Argenx Se (ARGX), Iridex (IRIX) and Keros Therapeutics (KROS)May 4, 2024 | Priority Gold (Ad)Biden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...March 27, 2024 | finance.yahoo.comIRIDEX Corporation (NASDAQ:IRIX) Q4 2023 Earnings Call TranscriptMarch 27, 2024 | washingtonpost.comIridex: Q4 Earnings SnapshotMarch 26, 2024 | globenewswire.comIridex Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 25, 2024 | markets.businessinsider.comIRIDEX earnings preview: what to expectMarch 20, 2024 | globenewswire.comIridex Schedules Fourth Quarter and Full Year 2023 Financial Results and Update on Strategic Review Process for March 26, 2024February 23, 2024 | benzinga.comIridex Stock (NASDAQ:IRIX), Short Interest ReportFebruary 23, 2024 | benzinga.comIridex Stock (NASDAQ:IRIX) Dividends: History, Yield and DatesDecember 28, 2023 | finance.yahoo.comIridex Confirms Medicare Administrative Contractors Retired Local Coverage Determinations that Restricted CyclophotocoagulationNovember 27, 2023 | finance.yahoo.comIridex Corporation Announces Successful Appeal for Revision of Recent Medicare LCDs to Provide Broader Coverage of CyclophotocoagulationNovember 17, 2023 | finanznachrichten.deIRIDEX Corporation: Iridex Reports Third Quarter 2023 Financial Results and Business UpdateNovember 14, 2023 | benzinga.comIridex: Q3 Earnings InsightsNovember 14, 2023 | finance.yahoo.comIridex Reports Third Quarter 2023 Financial Results and Business UpdateNovember 13, 2023 | finance.yahoo.comIridex to Host Third Quarter Financial Results Conference Call on November 14, 2023November 9, 2023 | morningstar.comIRIDEX Corp IRIXNovember 2, 2023 | msn.comIridex Reimbursement Chaos Presents Buying OpportunityNovember 1, 2023 | msn.comWall Street Set to Open Mixed Ahead of Federal Reserve MeetingNovember 1, 2023 | benzinga.comNasdaq Surges Over 100 Points Ahead Of Fed Decision; WeWork Shares PlungeNovember 1, 2023 | markets.businessinsider.comDow Gains Over 100 Points; Fed Leaves Interest Rates UnchangedSee More Headlines Receive IRIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IRIDEX and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/26/2024Today5/04/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorComputer and Technology Industry Electromedical equipment Sub-IndustryN/A Current SymbolNASDAQ:IRIX CUSIPN/A CIK1006045 Webwww.iridex.com Phone(650) 940-4700Fax650-940-4710Employees111Year Founded1989Price Target and Rating Average Stock Price Target$2.00 High Stock Price Target$2.00 Low Stock Price Target$2.00 Potential Upside/Downside-28.6%Consensus Rating Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)($0.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,570,000.00 Net Margins-18.45% Pretax Margin-18.28% Return on Equity-75.18% Return on Assets-25.99% Debt Debt-to-Equity RatioN/A Current Ratio2.12 Quick Ratio1.35 Sales & Book Value Annual Sales$51.87 million Price / Sales0.88 Cash FlowN/A Price / Cash FlowN/A Book Value$0.59 per share Price / Book4.75Miscellaneous Outstanding Shares16,253,000Free Float15,245,000Market Cap$45.51 million OptionableOptionable Beta0.82 Social Links 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. David I. Bruce (Age 65)President, CEO & Director Comp: $459.31kMr. Fuad Ahmad (Age 54)Interim Chief Financial Officer Comp: $424.9kMr. Patrick Mercer (Age 52)Chief Operating Officer Comp: $385.51kMs. Leigh SalvoHead of Investor RelationsKey CompetitorsCuteraNASDAQ:CUTRKey TronicNASDAQ:KTCCNortech SystemsNASDAQ:NSYSInuvoNYSE:INUVQuantumNASDAQ:QMCOView All Competitors IRIX Stock Analysis - Frequently Asked Questions What is IRIDEX's stock price target for 2024? 0 brokerages have issued 12 month target prices for IRIDEX's shares. Their IRIX share price targets range from $2.00 to $2.00. On average, they expect the company's share price to reach $2.00 in the next year. This suggests that the stock has a possible downside of 28.6%. View analysts price targets for IRIX or view top-rated stocks among Wall Street analysts. How have IRIX shares performed in 2024? IRIDEX's stock was trading at $2.81 at the start of the year. Since then, IRIX stock has decreased by 0.4% and is now trading at $2.80. View the best growth stocks for 2024 here. When is IRIDEX's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our IRIX earnings forecast. How were IRIDEX's earnings last quarter? IRIDEX Co. (NASDAQ:IRIX) released its earnings results on Tuesday, March, 26th. The medical equipment provider reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.05) by $0.13. The medical equipment provider earned $12.46 million during the quarter, compared to analyst estimates of $14.90 million. IRIDEX had a negative net margin of 18.45% and a negative trailing twelve-month return on equity of 75.18%. What is Theodore A. Boutacoff's approval rating as IRIDEX's CEO? 7 employees have rated IRIDEX Chief Executive Officer Theodore A. Boutacoff on Glassdoor.com. Theodore A. Boutacoff has an approval rating of 64% among the company's employees. What other stocks do shareholders of IRIDEX own? Based on aggregate information from My MarketBeat watchlists, some companies that other IRIDEX investors own include NVIDIA (NVDA), Trevena (TRVN), CTI BioPharma (CTIC), Agile Therapeutics (AGRX), Genocea Biosciences (GNCA), Idera Pharmaceuticals (IDRA), Lipocine (LPCN), Rigel Pharmaceuticals (RIGL) and SCYNEXIS (SCYX). How do I buy shares of IRIDEX? Shares of IRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IRIX) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldThe Gold Grab of the CenturyColonial MetalsStock-Picking AI Predicts #1 Stock of 2024AltimetryThe only AI company you should be looking atBehind the MarketsThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IRIDEX Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.